Observational studyMedicine2026
Comparison of in vitro fertilization outcomes between patients with and without polycystic ovary syndrome.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study aims to investigate the increased risk of adverse pregnancy outcomes on patients who have a polycystic ovary syndrome (PCOS) with high ovarian response. The data of patients (3841 cycles) with ovarian high response who conceive in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) in our hospital from January 2016 to June 2020 were picked out. According to with or without PCOS, the cycles were divided into PCOS group and non-PCOS group. After propensity score matching matching, 649 cycles in each group were analyzed. There was no significant difference in general conditions between the 2 groups (P > .05), but the Anti-Müllerian hormone (8.30 ± 3.96 vs 6.36 ± 3.42; P < .001***) and Antral follicle count (AFC) (22.71 ± 4.56 vs 19.56 ± 5.66; P < .001***) of PCOS group were significantly higher than those of non-PCOS group. No significant differences were found in the thickness of endometrium on the day of human chorionic gonadotropin (hCG) day (12.28 ± 2.38 vs 12.18 ± 2.41; P = .444) but progesterone (0.97 ± 0.57 vs 1.16 ± 0.69; P < .001***) was remarkably lower than that in non-PCOS group. Number of oocytes retrieved (23.33 ± 6.45 vs 22.57 ± 5.73; P = .025*), high-quality embryo rate (60.6 vs 53.6; P < .001***) and high-quality blastocyst rate (15.2 vs 11.5; P < .001***) were significantly higher in the PCOS group than those in the non-PCOS group. The rates of freezing all embryos cycles due to high ovarian response (52.4 vs 43.1; P = .001**), clinical pregnancy (84.2 vs 74.0; P = .012*) and live birth (73.8 vs 61.2; P = .001**) were all significantly higher in PCOS group than non-PCOS group, however, with no significant difference in the rates of preterm birth (6.3 vs 9.9; P = .153), ovarian hyperstimulation syndrome (OHSS) (3.5 vs 3.7; P = .179) and OHSS in clinical pregnancy (3.2 vs 3.8; P = .067) between the 2 groups were found. These findings suggest that tailored treatment protocols, including individualized ovarian stimulation strategies and careful management of OHSS, may optimize reproductive outcomes in high-response PCOS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.